TSC Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing aims to reduce risk while seeking solid outperformance on a total return basis.
The following ratings changes were generated on Friday, May 1.
We've downgraded BioMarin Pharmaceutical(BMRN) from hold to sell, driven by its generally disappointing historical performance in the stock itself, unimpressive growth in net income, generally weak debt management and feeble growth in its earnings per share.
Net income fell from $1.7 million in the year-ago quarter to -$13.2 million in the most recent quarter. BioMarin has a debt-to-equity ratio of 1.8, which is high compared with the industry average. It maintains a strong quick ratio of 4.9. EPS declined in the most recent quarter compared with the same quarter last year, and we feel the company is likely to report a decline in earnings in the coming year. Return on equity rose from the year-ago quarter. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,733.67 | 1,166.21 | 2,389.09 | 36.42 |
Oil *
81.99
|
|
UP
47.69
|
UP
6.75
|
UP
11.08
|
DOWN
0.11
|
10 Yr
3.64%
SPDR Gold
109.59
|
|
+0.45%
|
+0.58%
|
+0.47%
|
-0.30%
|
Data delayed 20 minutes |
Connect with TheStreet